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All human endeavors in drug development and 
therapeutics revolve around their optimization to 
offer efficacious proactive healthcare so as to 
improve public health with assured safety and 
market accessibility of the new products to 
people. Nanotechnology is emerging as one of 
the key technologies of the 21
st
 century and is 
expected to enable developments across a wide 
range of sectors that can benefit citizens. The 
dawn of nanotechnology can be traced back to 
1959, when Caltech physicist Richard Feynman 
painted a vision of the future of science. In a 
talk titled “There’s plenty of room at the 
bottom”, Feynman hypothesized that atoms and 
molecules could be manipulated like building 
blocks. (1) Nanotechnology began to emerge as 
a realistic scientific endeavor during the 1980s. 
In 1982, IBM researchers introduced the 
scanning tunneling microscope (STM), a 
microscope that could display individual atoms 
of gold. (2) Scientists’ abilities to utilize 
advancing nanotools were highlighted in 1989 
when IBM scientists manipulated thirty-five 
atoms of xenon to form the letter IBM. (3) The 
last decade has witnessed rapid technological 
advancements.  
Nanotechnology is the science of studying 
phenomena and the manipulation of materials at 
atomic, molecular and macromolecular scale. 
Use of the prefix "nano" in this context refers to 
a nanometer (nm). A nanometer is one-billionth 
of a meter. Dimensions between approximately 
1 and 100 nanometers are known as the 
"nanoscale". (4) 
Over millennia, nature has perfected the art of 
biology at the nanoscale. Many of the inner 
workings of cells naturally occur at the 
nanoscale. For example, hemoglobin, the 
protein that carries oxygen through the body, is 
5.5 nanometers in diameter. A strand of DNA, 
one of the building blocks of human life, is only 
about 2 nanometers in diameter.(5) Things like 
nanotubes are the nanomaterials that are 
engineered by picking up some members from 
Carbon family. The single walled nanotube is 
very popular for its applications in electronics. 
(6) But, a formulation scientist can make it 
functionalize to work as advanced drug delivery 
system for delivery of anticancer drug to the 
targeted tissue. (7) 
DISPARITIES IN DEFINING NANO- 
TECHNOLOGY AND NANOMEDICINE 
Nanotechnology 
One of the major problems that regulators, 
policy-makers, researchers, and lawyers 
continue to face regarding nanotechnology is the 
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confusion about its definition. (8, 9) Medicines 
and Healthcare products Regulatory Agency 
(MHRA) defines nanotechnology as the 
Production and application of structures, 
devices, and systems by controlling the shape 
and size of materials at nanometer scale. Scale 
ranges from the atomic level at around 0.2 nm 
up to around 100 nm.(10) The MHRA believes 
that current EU regulations for medicines and 
medical devices are sufficiently stringent and 
broad in scope to cover theoretically risks 
associated with nanotechnologies. (11) The 
USA National nanotechnology initiative, (NNI) 
defines nanotechnology as: “Nanotechnology is 
the understanding and control of matter at 
dimensions of roughly 1 to 100 nanometres, 
where unique phenomena enable novel 
applications. Encompassing nanoscale science, 
engineering and technology, nanotechnology 
involves imaging, measuring, modelling, and 
manipulating matter at this length scale. (12) 
The NNI definition excludes numerous devices 
and materials of micrometer dimensions (and 
also of dimensions less than 1 nm), a scale that 
is included within the definition of 
nanotechnology by many nanoscientists. (13) 
Japanese authorities in their Second Science and 
Technology Basic Plan have defined 
nanotechnology an interdisciplinary science and 
technology that encompasses IT technology, the 
environmental sciences, life sciences, materials 
science, etc. It is for controlling and handling 
atoms and molecules in the order of nano (1/1 
000 000 000) meter enabling discovery of new 
functions by taking advantage of its material 
characteristics unique to nano size, so that it can 
bring technological innovation in various fields. 
(14) 
One definition, not constrained by size, yet 
correctly emphasizing that controlled 
manipulation at the nanoscale results in medical 
improvements and/or significant medical 
changes, comes from the European Science 
Foundation (15): “The science and technology 
of diagnosing, treating and preventing disease 
and traumatic injury, of relieving pain, and of 
preserving and improving human health, using 
molecular tools and molecular knowledge of the 
human body. 
From the perspective of its applications in 
diverse fields, Nanotechnology cannot be 
considered as one technology but encompasses 
many technical and scientific fields such as 
medicine, chemistry, physics, engineering, 
biology, etc.  
Nanomedicine 
Nanomedicine is an application of 
nanotechnology in the areas of healthcare and 
disease diagnosis and treatment and prevention 
of disease. Nanomedicine has been defined as 
the monitoring, repair, construction and control 
of human biological systems at the molecular 
level, using engineered nanodevices and 
nanostructures. (16) Although nanoscales range 
from 1nm to 100 nms, in practice, nanomaterials 
beyond this scale often go into Nanomedicine 
development. For example, drug developed 
using nanotechnology (Abraxane`s albumin-
paclitaxel nanoparticles) demonstrates 
therapeutic efficacy and bioavailability and 
desired properties at scales greater that 100nm, 
(17) on the other hand, certain medical devices 
in Nanomedicines scale below even 1 nm. (18) 
At present, there are no uniform, internationally 
accepted definitions of nanotechnology as well 
as Nanomedicine and it continues to be the 
major area of controversy.   
FDA has neither adopted the NNI’s definition 
for its own regulatory purposes nor has it 
established a formal regulatory definition of 
nanomaterials, nanoscale, nanotechnology or 
Nanomedicine. Some experts suggest that the 
size limitation imposed in NNI’s definition 
should be removed especially for 
Nanomedicines where the phrase “small 
technology” may be more appropriate to 
accurately encompass both nanotechnologies 
and micro-technologies. (19) 
NANOMEDICINE MARKET The market 
projections for medically oriented 
Nanotechnologies show that Nanomedicine 
market was USD 78.54 billion in 2012 and is 
expected to reach a value of USD 177.60 billion 
in 2019, growing at a CAGR of 12.3% from 
2013 to 2019.(20) Increase in the Compound 
Annual Growth Rate (CAGR) for 
Nanomedicines market is due to two reasons: 1) 
Increased funding by Government and Private 
Institutions to foster R&D and 
commercialization of Nanomedicines in the area 
of neuro, cardiovascular and oncology 
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applications (21), and 2) Increase in the geriatric 
population, rise in the chronic diseases/ 
disorders and high unmet medical needs where 
Nanomedicines is a great hope! (20) There are 
over 70 Nanomedicine products marketed 
Worldwide. (22) The growth of nanotechnology 
is exponential, during the year 2000 to 2008, 
worldwide growth of nanotechnology patent 
applications was about 34.5%. USA has filed 
19,665 patent applications followed by China 
18,438 and Japan with 10,763 patent 
applications during the year 1991 to 2008. (23- 
25) 
APPLICATIONS OF NANAOMEDICINES 
Figure 1 represents Nanomedicine application 
field breakdown. Among the different 
application fields of Nanomedicines, the drug 
delivery market is the largest contributing 
segment.(26) Nanomedicine includes several 
distinct application areas that fall under 6 
medical sectors: 1) advanced drug delivery 
systems 2) drug therapies 3) in-vivo imaging 
 
4) in-vitro Diagnostics 5) biomaterials and 
active implants and 6) cosmetics 
CURRENT REGULATIONS FOR 
APPROVAL OF NANOMEDICINES At 
present, Nanomedicine products are regulated as 
medicinal products or as medical devices and 
there is currently no specific regulatory 
framework for nanotechnology-based products 
neither in the EU nor in the USA. Current 
regulation for Nanomedicines in the USA 
follows FDA Guidelines effective from 3 June 
2010 CDER MAPP 5015.9. (27) In EU, 
Nanomedicines are considered within existing 
guidelines on a product-by-product basis. There 
is a “reflection” paper on nanotechnology based 
medicinal products for human use 
(EMEA/CHMP/79769/2006). In Japan, 
Nanomedicines are regulated within the 
framework of the Pharmaceutical Affairs law on 
a product-by-product basis. (27)  
New drug delivery systems (NDDS) are always 
approved in combination with the drug they 
deliver and they are regulated as drugs because 
the delivery system interacts with the drug and 
can change its efficacy and safety profile. Some 
therapies in which nanoparticles have no direct 
therapeutic effect are regulated as medical 
devices. Examples are hyperthermia with iron 
nanoparticles or cell therapy using nanoparticles 
for cell sorting. (28) Nanoparticle-based contrast 
agents that are administered intravenously, on 
the other hand, are regulated as drugs. 
REGULATORY PROBLEMS / ISSUES 
FOR NANOMEDICINES 
Emerging technologies bring with them 
concerns and uncertainties about how they 
should be regulated. (29) To facilitate the 
regulation of nanoproducts, the FDA has formed 
an internal nanotechnology interest group 
(NTIG) composed of representatives from all its 
regulatory centers. The Nanotech Task Force in 
2007 issued an FDA task force report, but as of 
March 2011, no clear guidelines or regulations 
have been proposed by the task force. (30) So, 
the FDA currently regulates nanoproducts but 
not the technology. The conclusion by the FDA 
has been criticized by many experts because of 
the questionable assumption on which it is 
based. (31) In other words, the nanoproducts 
were approved based on the safety data of their 
‘non-nano versions’(bulk counter parts).  
CHALLENGES POSED BY NANO- 
MEDICINES The two main regulatory 
problems posed by Nanomedicine are as 
follows: 1) classification problem, and 2) 
problem of scientific expertise Substantive steps 
are needed to prepare for these problems in the 
context of Nanomedicine.  
1) Classification problem: The first significant 
regulatory dilemma posed by products based on 
nanotechnology is that of classification. 
Although the current classification system has 
been applied to other emerging technologies, the 
 
Figure 1. Application segments of 
nanomedicines. (26) 
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miniaturization of medical products compounds 
the problems associated with regulating 
combination products and blur the distinction 
between the different categories of products to a 
greater degree than ever before. Till the advent 
of advancing medical technologies, FDA 
classified medical products for regulatory 
purposes as drugs, devices, and biologics. 
Advancing medical technologies combine drugs, 
devices and biologics often; hence the fourth 
category for combination products was created 
in 1990. (31) In 1991, agreements were formed 
between CDER and CBER, CDRH and CDER 
(32) 
 
and CDRH and CBER (33)
 
establishing 
guidelines for determining which center has 
primary jurisdiction over a combination product. 
In 1999, a Device Action Plan was launched to 
make CBER`s review of combination products 
more consistent with how they would be 
reviewed by CDRH. (34) If a product combines 
a drug and biologic, a drug and device, or a 
biologic and device, it is a combination product. 
(35) The product’s primary mode of action 
determines which center has primary 
jurisdiction over the product.
 
A manufacturer 
can submit a request to have the product 
characterized as a drug, biologic, device, or 
combination product
 
and the intent of the 
manufacturer is often evaluated as evidence of 
how the product should be classified. (36, 37) 
The request for the product class comes from 
the Manufacturer. (38) The manufacturer may 
prefer to target a particular center for its 
tendency to evaluate certain types of evidence or 
the fact that it does not charge user fees! The 
real challenge faced in classification of 
nanotechnology based products lies in their 
difficulty in characterizing the primary mode of 
action. This is due to the fact that the 
miniaturization of medical products would lead 
to an increase in the combination products. (37)  
For example, when dendrimers or nanoshells are 
the drug delivery devices, they are activated by 
IR light. (39) So it’s unclear how these novel 
drug delivery systems should be regulated.  
2) Lack of scientific expertise. It is 
undoubtedly true that scientific expertise is 
critical to effective Regulation. The regulatory 
authorities have recognized the importance of 
strong science base since 2001 and it is reflected 
in performance plan. (40) However, taking an 
example of nanorobots, they can enter into our 
systemic circulation and deliver the drug just in 
right dose and at the right place. A big question 
is whether the decision makers are scientifically 
able to judge the advanced technology and 
safety of such products for marketing especially 
when the tissue toxicity with Nanomedicines is 
not well understood. (41) A dedicated 
nanotoxicological evaluation system is still 
lacking. (27) 
Toxicity of the engineered nanoparticles: 
Engineered Nanoparticles could themselves 
induce toxicity if they are sensed as antigenic 
challenge by our immune system. (42) This 
cannot be overlooked as it would create a worse 
situation for the patients. The most significant 
parameters of the engineered nanoparticles with 
respect to nanotoxicity are size, shape, specific 
surface area, agglomeration/aggregation state, 
size distribution, surface morphology, 
crystallinity, solubility, molecular structure, 
composition of nanoparticles, phase identity, 
surface chemistry including composition, 
charge, tension, reactive sites, physical 
structure, photo-catalytic properties and zeta 
potential. (43) The need for separate 
toxicological assays of nanoproducts is because 
nanoparticles not only possess unique size 
specifications, but the novel properties they 
show are different from their bulk counterparts. 
There are Nanomedicines that involve 
subcutaneous or intravenous injectible 
Nanoparticulate systems. (44) These carry and 
deliver the drug directly into human body 
bypassing the normal absorption processes. 
These Nanoparticulate carriers may be 
responsible for the toxicity as they would 
interact with the biological macromolecules and 
result in toxicity. Alternately, insoluble NPs can 
accumulate inside tissues or organs and lead to 
toxicity. The risks of toxicity associated with 
exposure to nanoparticles are as shown in figure 
2. 
OUR PROPOSAL:  
Having seen the gravity of the problems in 
regulation and toxicity issues related to 
Nanomedicines, the authors wish to propose 
certain measures towards managing these better 
if not completely. 
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Figure 2. Toxicity of nanoparticles. (43) 
The proposal has 8 steps: 1) Identify Unique 
safety issues, 2) Correlate physicochemical 
properties of nanoparticles with in-vivo 
behaviour and therapeutic outcome, 3) Improve 
the understanding of transport process of these 
nanoproducts in cell membranes 4) Determine 
the complete Pharmacokinetic Profile of the 
product 5) Develop standards to correlate 
biodistribution with safety and efficacy 6) 
Create a robust Databank of interactions 
between nanomaterials and biological systems 
7) Standardization of nanomaterials, protocols, 
refining of definitions and classification, explore 
International Harmonizing efforts and treaties 
and 8) Specify regulatory submissions. 
Step 1: Identify safety issues unique to 
Nanomedicines 
Safety issues unique to Nanomedicines have to 
be identified by carrying out In vitro toxicity 
studies, In vivo toxicity studies and QNAR 
Modeling. In-vitro toxicity studies for 
Nanomedicines offer rapid and effective end 
points to assess the toxicity of the engineered 
Nanomedicines. These studies offer the 
following advantages:  
(a) Mechanism-driven evaluations, 
(b) Dose-response relationships,  
(c) Suitable for high throughput screening,  
(d) System for studying the structure activity 
relationships,  
(e) Identify the mechanisms of toxicity in the 
absence of physiological and compensatory 
factors that confound the interpretation of whole 
animal studies,  
(f) Efficient and cost-effective, 
(g) Assist in designing in-vivo animal studies. 
 
In-vivo toxicity studies for establishing safety 
of the engineered nanoparticles use the 
constitution of organism outside the organism. 
The influence of various factors may not be 
available in in-vitro experimental environment. 
Hence, it is essential to confirm the result using 
appropriate animal model. The organisation for 
economic co-operation and development 
(OECD) guideline for the testing of chemicals 
has been implemented for many toxicological 
endpoints. 
The guidelines given by OECD as shown in fig. 
3 should be applied for nanoengineered 
materials in their nano versions and not in their 
bulk counterparts.   
Quantitative Nanostructure - Activity 
Relationship (QNAR) Modeling: 
Presently, the FDA has not established or 
applied comparable PbPK or QSAR models to 
nanomaterials. (45)  Experimental toxicological 
 
Figure 3. OECD guidelines for toxicity testing. (43) 
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studies are lengthy, costly, and often not 
feasible. In such cases, In silico structure 
activity relationship assays should be developed 
for nanostructured materials/ nanoproducts. This 
would be economically feasible, yet with a high 
predictive power in the early stages of drug 
discovery and development.  
Step 2: Correlate physiochemical properties 
with In vivo biological behaviour and 
therapeutic outcome. 
Physico-chemical properties of nanoparticles 
such as size, surface charge, stability, density, 
crystallinity, surface characteristics, and 
solubility can impact on biodistribution. Since 
the nanoscaled products show distinct and 
unique physicochemical properties, they must 
be evaluated to establish correlation with the 
biological behavior, or pharmacokinetic profile 
(ADMET) profile and mechanism of action to 
finally the therapeutic outcome. 
Step 3: Improve understanding of mass 
transport across membranes and body 
compartments. 
Membrane permeability assays using cell 
culture techniques have been used for 
pharmacokinetic studies, they should also be 
used for nanomedicinal products. There is a 
need to search for suitable model systems fit for 
the permeation assays while testing 
nanomaterial based products.  
Step 4: Determine complete pharmacokinetic 
profile of the product. 
Information about accurate bio-distribution 
profiles following systemic administration via 
any route is valuable to determine 
bioavailabiliy, dose and dosing regimen of the 
product.  
Step 5: Develop standards to correlate bio-
distribution with safety and efficacy 
This should be done by using parameters like 
size, surface charge, stability, surface 
characteristics, solubility, crystallinity, density, 
etc.  
Step 6: Create a robust databank relating the 
interactions between nanomaterials and 
biological systems 
Adapt existing methodologies and develop new 
paradigms for evaluating safety and efficacy 
data of Nanomedicines. 
- Develop the guidance that provides specifics 
as to what kind of data is needed. 
- Share the data in an internationally harmonized 
environment. 
Data evaluation, Data sharing in international 
harmonized environment should be done taking 
into consideration additional dimension in 
addition to classical immunological, metabolic 
and pharmacological functions. What we mean 
by this is the novel properties intrinsic to 
nanomaterial and products thereof should be 
studied and standardized using validated 
analytical methods and, both qualitative and 
quantitative data should be generated.  
Step 7: Standardization of nanomaterials, 
protocols, refining of definitions and 
classification, explore International 
Harmonizing efforts and treaties. 
• Create reference classes for nanomaterials 
that are synthesized and characterized. 
• Develop consensus testing protocols to 
provide benchmarks for the creation of 
classes of Nanomedicines. 
• Create uniform standards for and/or working 
definitions of nanomaterials. 
• Refine the current definitions of 
nanomaterial, nanotechnology, nanoscale 
and Nanomedicine. 
• Explore international harmonization efforts 
and formal treaties. 
• Involve standard - setting organizations such 
as the International Organization for 
Standardization (ISO) and ASTM 
International. 
• Consult and collaborate with other federal 
agencies in a more effective manner. 
Step 8: Classification and Regulatory 
submissions 
Re-evaluation of the current FDA classification 
scheme developing a system of classification 
based on function and/or risk of potential harm 
is required. Nanoversions of therapeutics should 
be subjected to completely new drug application 
process (NDA) and not merely the current 
Abbreviated New Drug Application (ANDA) 
process. (19) The screening and evaluation of 
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novel nanomedicinal products should 
incorporate dedicated screens for nanomaterial 
used in the product development.  
CONCLUSION 
Although the FDA’s current approach of 
classification and approval of nanotechnology 
based products lacks specificity, the FDA 
cannot develop more specific guidelines until it 
collects more data, establishes valid testing 
criteria, and answers important questions 
regarding the regulation of these products. (45-
47) The FDA needs to acquire a greater 
understanding of the toxicity and other 
properties of nanomaterials before it can 
establish new guidelines for nanoproducts. More 
data are also needed to help the FDA determine 
what, if any, additional testing should be 
required during agency evaluation of products 
containing nanomaterials. For example, the size 
boundary at which data regarding larger 
particles of a particular material become 
irrelevant to NPs is currently unknown. In 
addition, only limited data are available 
regarding the metabolism and toxicity of NPs, 
including excretion, translocation, 
carcinogenicity, and immunological or 
genotoxic effects. Such findings are relevant to 
evaluating toxicity, biocompatibility, and the 
potential distribution of NPs in the body. Long-
term toxicity data for many nanomaterials are 
also currently unavailable. The biopersistence of 
inorganic NPs, which can build up in the body, 
must also be studied extensively in animals 
before they can be approved for use in human 
applications. As Nanomedicines are evolving 
rapidly on the pharmaceutical landscape, it is 
also important to continuously distribute new 
information and provide ongoing training in 
order to conduct an FDA review process that is 
timely, informed, and based on the most current 
science. Regulation of Nanomedicines requires 
a proper balance between “underregulation,” 
which could cause inappropriate and possibly 
harmful product approvals, and overregulation, 
which could limit innovation. (45)  
In a nutshell, to dive successfully in the  tide of 
innovation; regulation of Nanomedicines should 
be based on the strong evidence based scientific 
knowledge of the nanomaterial gained by 
harmonized efforts with advanced validated 
methods of evaluation where scientists of varied 
disciplines as well as regulatory agencies join 
hands to support the development of product 
that fits for the challenging unmet medical needs 
and yet regulated with scientific confidence to 
ensure safe, efficacious product reaching the 
market place and protection of public health.  
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